A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform
1 other identifier
observational
17,111
1 country
1
Brief Summary
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2026
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2026
CompletedFirst Posted
Study publicly available on registry
June 30, 2026
CompletedStudy Start
First participant enrolled
June 30, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 30, 2026
July 16, 2026
July 1, 2026
5 months
June 24, 2026
July 15, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Number of Patients by Prior Therapies
Baseline
Number of Patients by Number of Post-index Lines of Therapy (LOTs)
Up to approximately 5 years
Number of Patients by Type of Therapy at Each LOT
Up to approximately 5 years
Percentage of Patients Switching From One Type of Therapy to Another at Each LOT
Up to approximately 5 years
Time to First-line (1L) Treatment Initiation (TTTI)
Time from index date (mCRPC diagnosis) to the start of 1L treatment.
Up to approximately 5 years
Time to Next Therapy (TTNT) for Each LOT
Time from the end of each LOT to initiation of the next LOT.
Up to approximately 5 years
Secondary Outcomes (6)
Number of Patients by Patient Characteristics
Baseline
Age
Baseline
Progression-free Survival (PFS) From Index Date
Up to approximately 5 years
PFS From Each LOT
Up to approximately 5 years
Overall Survival (OS) From Index Date
Up to approximately 5 years
- +1 more secondary outcomes
Study Arms (1)
mCRPC Cohort
Adult male patients with a recent diagnosis of mCRPC in PRECISION.
Eligibility Criteria
Adult male patients with a confirmed mCRPC diagnosis in the US in the last 5 years who are included in the PRECISION data platform.
You may qualify if:
- Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
- Male sex at index, where index is the date of initial mCRPC diagnosis.
- Age 18 years at index.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Novartis
East Hanover, New Jersey, 07936, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Central Study Contacts
Novartis Pharmaceuticals
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2026
First Posted
June 30, 2026
Study Start
June 30, 2026
Primary Completion (Estimated)
November 30, 2026
Study Completion (Estimated)
November 30, 2026
Last Updated
July 16, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share